• contract

Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-Regional Partnership to Commercialize RNAi Therapeutics

PRNewswire March 9, 2023

ZUG, Switzerland, March 9, 2023 /PRNewswire/ –┬áAlnylam Pharmaceuticals, Inc.┬á(Nasdaq: ALNY), the leading RNAi therapeutics company, and Medison┬áPharma┬á(“Medison”), a global pharma company focused on providing access to highly innovative therapies for patients in international markets, have announced an expansion of their existing partnership to a multi-regional agreement that includes Poland,┬áCzech Republic, Hungary, Slovakia, Lithuania,┬áEstonia┬áand┬áLatvia, in addition┬áto Israel.┬á

Medison Pharma Logo

This new agreement builds upon┬áthe successful long-term partnership between Alnylam and Medison in Israel and will allow Alnylam┬áto utilize Medison’s unique multi-regional platform to ensure that Alnylam’s innovative RNA interference (RNAi) therapeutics, such as ONPATTRO┬« (patisiran), GIVLAARI┬« (givosiran), and OXLUMO┬« (lumasiran)┬áare made available across additional countries in Europe. This expanded agreement is intended to ensure more efficient and effective commercialization. GIVLAARI┬« and OXLUMO┬« have already been approved for reimbursement in Poland, and Alnylam and Medison will work together to obtain additional reimbursements in the territories.

“We are delighted to extend our existing relationship with Medison, which will enable us to enhance our presence and┬ábring the benefits┬áof Alnylam’s┬áinnovative RNAi therapeutics to patients in Central and Eastern Europe,” said┬áNorton Oliveira, Senior Vice-President and Head of Partner and Emerging Markets at Alnylam. “Medison is already one of┬áour most significant partners,┬áand their┬áteam has a wealth of experience to offer across our new markets. We look forward to continuing our collaboration and transforming more patients’┬álives together.”

“The trust Alnylam┬áshows in Medison’s multi-regional commercial platform allows us to broaden patient access to Alnylam’s highly innovative therapies across more countries,” said Meir Jakobsohn, Founder and CEO of Medison.┬á”Expanding our successful partnership will enable us to provide access to patients across Central and Eastern Europe┬áwho might otherwise not have access to these innovative treatment options.”

“We are privileged to expand the access of Alnylam’s┬ágroundbreaking┬átreatments┬áto additional markets. “Medison’s multi regional platform makes us the partner┬áof┬áchoice for emerging biotech companies seeking to make their innovative products available in international markets for the benefit of patients suffering from rare, debilitating disease”, said┬áGil Gurfinkel, VP Corporate Development at Medison

About RNAi
RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. Its discovery has been heralded as “a major scientific breakthrough that happens once every decade or so,” and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines known as RNAi therapeutics is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam’s RNAi therapeutic platform, function upstream of today’s medicines by potently silencing messenger RNA (mRNA) ÔÇô the genetic precursors ÔÇô that encode for disease-causing or disease pathway proteins, thus preventing them from being made. This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases.

About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals┬á(Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding 20 years ago,┬áAlnylam┬áhas led the┬áRNAi Revolution┬áand continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products are ONPATTRO┬«┬á(patisiran), GIVLAARI┬«┬á(givosiran), OXLUMO┬«┬á(lumasiran), AMVUTTRA┬«┬á(vutrisiran) and Leqvio┬«┬á(inclisiran), which is being developed and commercialized by Alnylam’s partner, Novartis.┬á Alnylam┬áhas a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development.┬áAlnylam┬áis executing on its “Alnylam P5x25″ strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile.┬áAlnylam┬áis headquartered in┬áCambridge, MA.┬á

About Medison Pharma
Medison is a global pharma company focused on providing access to highly innovative therapies to patients in international markets.

Medison is the first to create an international commercialization platform for highly innovative therapies, helping to save and improve lives by making the best available novel treatments accessible to patients in international markets. Medison has a track record of multi-territorial partnerships with leading pharmaceutical and biotech companies seeking to expand their global reach.

To learn more visit www.medisonpharma.com

Contacts:

Alnylam Pharmaceuticals
Fiona McMillan, Head of Communications, International
T: +44 7741 655 570
E: fmcmillan@alnylam.com

Medison Pharma
Inbal Chen, Corporate Communications
T: +972-54-4400784
E: inbalc@medisonpharma.com

 

Alnylam Pharmaceuticals Logo

 

SOURCE Medison Pharma; Alnylam Pharmaceuticals

AAPR aggregates press releases and media statements from around the world to assist our news partners with identifying and creating timely and relevant news.

All of the press releases published on this website are third-party content and AAP was not involved in the creation of it. Read the full terms.